203435-53-4

Basic information

• Product Name: Carbamic acid, (4-aminobutoxy)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (4-aminobutoxy)-, 1,1-dimethylethyl ester (9CI);tert-butyl 4-aMinobutoxycarbaMate;CarbaMic acid, (4-aMinobutoxy)-, 1,1-diMethylethyl ester;tert-butyl N-(4-aminobutoxy)carbamate
• CAS NO: 203435-53-4
• Molecular Formula: C₉H₂₀N₂O₃
• Molecular Weight: 204.2667
• Product Categories: N-BOC
• Mol File: 203435-53-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, (4-aminobutoxy)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (4-aminobutoxy)-, 1,1-dimethylethyl ester (9CI)(203435-53-4)
• EPA Substance Registry System: Carbamic acid, (4-aminobutoxy)-, 1,1-dimethylethyl ester (9CI)(203435-53-4)

Safety Data

• Hazardous Substances Data: 203435-53-4(Hazardous Substances Data)

Usage

Uses

Used in Chemical Reactions and Organic Synthesis:
Carbamic acid, (4-aminobutoxy)-, 1,1-dimethylethyl ester (9CI) is utilized as a reagent in chemical reactions and organic synthesis, playing a crucial role in the formation of various compounds and contributing to the advancement of chemical research and development.
Used in Pesticide Formulation:
This chemical compound is known for its potential use as a pesticide, where it can be incorporated into formulations to help control, repel, or kill pests. Its application in this field highlights its versatility and the broad range of industries it can serve.
Used as a Pharmaceutical Intermediate:
In the pharmaceutical industry, Carbamic acid, (4-aminobutoxy)-, 1,1-dimethylethyl ester (9CI) is recognized as a valuable intermediate. It is used in the synthesis of various pharmaceutical products, contributing to the development of new medications and therapies that can improve human health and well-being.

Upstream product

• 844696-48-6 tert-butyl 4-(1,3-dioxoisoindolin-2-yl)butoxycarbamate phthalimide 
• 1356966-77-2 tert-butyl 4-azidobutoxycarbamate 

Downstream Products

• 1356966-82-9 tert-butyl 4-(3-amino-4-(tritylthio)benzamido)butoxycarbamate 
• 1356966-80-7 tert-butyl 4-(3-nitro-4-(tritylthio)benzamido)butoxycarbamate 
• 1356966-78-3 C₃₆H₄₇N₃O₆S 
• 1356966-83-0 tert-butyl 4-(3-amino-4-((tritylthio)methyl)benzamido)butoxycarbamate 
• 69182-55-4 O-(4-aminobutyl)hydroxylamine 

Relevant articles and documents

Chemoproteomic Profiling of Phosphoaspartate Modifications in Prokaryotes

Phosphorylation at aspartic acid residues represents an abundant and critical post-translational modification (PTM) in prokaryotes. In contrast to most characterized PTMs, such as phosphorylation at serine or threonine, the phosphoaspartate moiety is intr

Intracellular Delivery of Native Proteins Facilitated by Cell-Penetrating Poly(disulfide)s

Intracellular delivery of therapeutic proteins is highly challenging and in most cases requires chemical or genetic modifications. Herein, two complementary approaches for endocytosis-independent delivery of proteins to live mammalian cells are reported. By using either a “glycan” tag naturally derived from glycosylated proteins or a “traceless” tag that could reversibly label native lysines on non-glycosylated proteins, followed by bioorthogonal conjugation with cell-penetrating poly(disulfide)s (CPDs), we achieved intracellular delivery of proteins (including antibodies and enzymes) which, upon spontaneous degradation of CPDs, led to successful release of their “native” functional forms with immediate bioavailability.

Design and Synthesis of an RGD Peptidomimetic-Paclitaxel Conjugate Targeting α v β 3 Integrin for Tumour-Directed Drug Delivery

A 1,2,3-triazole-based RGD peptidomimetic having nanomolar affinity for α v β 3 integrin was conjugated to the potent antimitotic paclitaxel via an oxime heterobifunctional linker. The resulting construct maintained nanomolar binding

Aldehyde-mediated bioconjugation: Via in situ generated ylides

A technically simple approach for rapid, high-yielding and site-selective bioconjugation has been developed for both in vitro and cellular applications. This method involves the generation of maleimido-phosphonium ylides via 4-nitrophenol catalysis under physiological conditions followed by their Wittig reactions with aldehyde-appended biomolecules.

Diverse organo-peptide macrocycles via a fast and catalyst-free oxime/intein-mediated dual ligation

Macrocyclic Organo-Peptide Hybrids (MOrPHs) can be prepared from genetically encoded polypeptides via a chemoselective and catalyst-free reaction between a trifunctional oxyamino/amino-thiol synthetic precursor and an intein-fusion protein incorporating a bioorthogonal keto group.

C-Terminal Attachment of Two Chemical Groups to Peptides

The present invention relates to a method for C-terminal attachment of two property-modifying groups to a peptide.

Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers

Insulin conjugated with structurally well defined, bifurcated and trifurcated polymers can be use by pulmonary delivery for systemic absorption through the lungs to reduce or eliminate the need for administering other insulins by injection.

C-Terminally Pegylated Growth Hormones

Conjugated growth hormones of the structure (I) are provided together with methods for manufacturing said conjugates. The conjugates are useful in therapy.

N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES

The invention is concerned with N-terminally pegylated polypeptides capable of binding to the prolactin receptor. Such polypeptides may for instance be N-terminally pegylated antagonists of the prolactin receptor, such as for instance prolactin variants.

C-Terminally PEGylated hGH-derivatives

A two-step strategy was used for the preparation of C-terminally PEGylated hGH-derivatives. In a first step a CPY-catalyzed transpeptidation was performed on hGH-Leu-Ala, introducing reaction handles, which were used in the second step for the ligation of